AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.
Exhibit 3
Financings By Type ($m)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
